The significant body of work described above showing that stromal cGAS–STING activation in response to DNA damage leads to anti-tumor immune responses has led to enthusiasm in terms of pharmacologically activating this pathway to enhance therapeutic efficacy and tumor control both pre-clinically and clinically. This evidence concerns the gene STING1 and neoplasm.